MS Oral Options Warrant Cautious Optimism

Sanofi-Aventis, which is developing teriflunomide, funded TEMSO. Dr. Miller, Dr. Wolinsky, and many of their associates in the study disclosed relationships with Sanofi-Aventis and with numerous other companies that make therapies for multiple sclerosis. Three coinvestigators were employees of Sanofi-Aventis.

The challenge of the oral drugs will come from a lack of guidance on which drug or drugs to prioritize in treatment.

Source DR. KITA

Both teriflunomide doses reduced the annualized relapse rate by approximately 31%, compared with placebo.

Source DR. MILLER